520
Participants
Start Date
May 31, 2003
Primary Completion Date
January 31, 2005
Study Completion Date
July 31, 2012
MabThera/Rituxan
1
Methotrexate
2
Placebo
3
Dublin
Brussels
Brussels
Lillehammer
Drammen
Liège
Ghent
Tromsø
New York
Berlin
Manhasset
Smithtown
Albany
Rochester
Arenzano
Genoa
Duncansville
Philadelphia
Philadelphia
Philadelphia
Milan
Baltimore
Brescia
Durham
Greenville
Toulouse
Orlando
Udine
Fort Lauderdale
Jupiter
Delray Beach
Boca Raton
Largo
Montpellier
Birmingham
Tours
Ratingen
Mayfield
Cleveland
Dayton
Indianapolis
Lansing
Kalamazoo
Madison
Madison
Rochester
Pisa
Chicago
Chicago
St Louis
St Louis
Strasbourg
Shreverport
Little Rock
Oklahoma City
Oklahoma City
Tulsa
Dallas
Dallas
Paris
Rouen
Waco
Houston
Amarillo
Meridian
Boise
Coeur d'Alene
Salt Lake City
Mesa
Paradise Valley
Tucson
Los Angeles
Los Angeles
Pasadena
Upland
La Jolla
Rancho Mirage
Fullerton
Santa Maria
Le Kremlin-Bicêtre
Palo Alto
Würzburg
Seattle
Seattle
Spokane
Haifa
Haifa
Petah Tikva
Ramat Gan
Tel Aviv
Jerusalem
Danbury
Indianapolis
Boston
Chapel Hill
Cincinnati
Burlington
Calgary
Edmonton
Vancouver
Hamilton
London
Toronto
Toronto
Dresden
Leipzig
Cork
Amsterdam
Oslo
Cannock
Leeds
London
Manchester
Metropolitan Borough of Wirral
Newcastle upon Tyne
Collaborators (1)
Biogen
INDUSTRY
Hoffmann-La Roche
INDUSTRY